APA (7th ed.) Citation

Pasi, K. J., Fischer, K., Ragni, M., Kulkarni, R., Ozelo, M. C., Mahlangu, J., . . . Oldenburg, J. (2020). Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study. Haemophilia : the official journal of the World Federation of Hemophilia, 26(6), e262-e271. https://doi.org/10.1111/hae.14036

Chicago Style (17th ed.) Citation

Pasi, K. John, et al. "Long‐term Safety and Sustained Efficacy for Up to 5 years of Treatment with Recombinant Factor IX Fc Fusion Protein in Subjects with Haemophilia B: Results from the B‐YOND Extension Study." Haemophilia : The Official Journal of the World Federation of Hemophilia 26, no. 6 (2020): e262-e271. https://doi.org/10.1111/hae.14036.

MLA (9th ed.) Citation

Pasi, K. John, et al. "Long‐term Safety and Sustained Efficacy for Up to 5 years of Treatment with Recombinant Factor IX Fc Fusion Protein in Subjects with Haemophilia B: Results from the B‐YOND Extension Study." Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 26, no. 6, 2020, pp. e262-e271, https://doi.org/10.1111/hae.14036.